Every material Form 8-K Dianthus Therapeutics, Inc. /DE/ has filed with the SEC since June 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Dianthus Therapeutics reported a third-quarter 2026 net loss of $46.6 million, or $0.81 per share, up from $36.8 million, or $0.97 per share, a year earlier. Higher research and development and general and administrative costs drove the increase, while the company reported about $1.2 billion in cash, cash equivalents and investments as of September 30, 2026, which it projects will fund operations into 2030.
Q3 2026 net loss was $46.6 million, or $0.81 per share, versus $36.8 million, or $0.97 per share, in Q3 2025.
R&D expenses rose to $45.6 million from $32.5 million, mainly on higher clinical costs and headcount.
G&A expenses rose to $14.1 million from $8.2 million, mainly due to increased headcount.
Phase 2 MoMeNtum top-line results for claseprubart in MMN are expected in December 2026.
Dianthus Therapeutics reported second-quarter 2026 results on August 4, 2026, with a net loss of $50.2 million, or $0.90 per share, compared with $31.6 million, or $0.88 per share, a year earlier. Research and development and general and administrative expenses both rose, which the company attributed to clinical costs and higher headcount for its claseprubart programs. The company said its roughly $1.2 billion in cash, cash equivalents and investments is projected to fund operations into 2030.
Net loss of $50.2 million, or $0.90 per share, for the quarter ended June 30, 2026, versus $31.6 million, or $0.88 per share, a year earlier
R&D expenses were $48.7 million, up from $26.3 million, mainly due to higher clinical costs and headcount
G&A expenses were $13.6 million, up from $8.9 million, mainly due to increased headcount
Cash, cash equivalents and investments were about $1.2 billion as of June 30, 2026, projected to provide runway into 2030
On June 11, 2026, Dianthus Therapeutics posted an updated corporate presentation with interim responder analysis for the first 40 patients to complete Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The presentation reports a 75% response rate, and the company says it supports potential best-in-disease efficacy. The filing notes the analysis covers a limited number of patients and may not predict results for remaining Part A patients or Part B.
Observed 75% response rate from the first 40 participants to complete CAPTIVATE Part A, per the presentation.
Company guidance: Phase 3 CIDP Part B top-line guidance by year-end 2026.
Cash, cash equivalents and investments of about $1.2 billion as of March 31, 2026, with runway expected into 2030.
Presentation filed as Exhibit 99.1, dated June 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Dianthus Therapeutics, Inc. /DE/ filing is on SEC EDGAR ↗. 8-K briefs of other companies →